紀錄類型 : 書目-語言資料,印刷品: 單行本
其他作者 : Stahl, Stephen M.,
出版項 : Cambridge, United Kingdom ;Cambridge University Press,2021.
面頁冊數 : xxii, 522 pages :color illustrations ;23 cm.
內容註 : Part I. Treatment Strategies -- Part II. Medication Reference Tables.
簡介 : "In community settings, the most common barriers to independent living, employment, and stable interpersonal relationships for patients suffering from schizophrenia-spectrum disorders or other psychotic disorders are negative symptoms and cognitive deficits. In contrast, severely mentally ill individuals, often incarcerated or chronically institutionalized, more frequently experience substantial barriers related to positive psychotic symptoms leading to problematic behaviors such as aggression or violence. This is not to say that among the chronically institutionalized severely mentally ill population that positive psychotic symptoms are the only, or even majority, source of problematic behaviors. A survey conducted within the California Department of State Hospitals, a circa 7000-bed system dedicated to the treatment of conserved and forensically committed patients, reviewed 839 episodes of aggression or violence by 88 persistently aggressive inpatients and found that 54% of such episodes were impulsive, 39% were predatory or instrumental, and 17% were psychotically driven. Nevertheless, amelioration or control of positive psychotic symptoms commonly forms the initial treatment focus among the severely mentally ill."--
標題 : Psychopharmacology - methods. -
標題 : Psychoses - Chemotherapy. -
標題 : Drug resistance. -
標題 : Psychotic Disorders - complications. -
標題 : Antipsychotic Agents - pharmacology. -
標題 : Drug Resistance. -
ISBN : 9781108965682
ISBN : 1108965687
LEADER 02543cam 2200337 i 4500
001 39977
005 20230203164052.0
008 230731t20212021enka b 001 0 eng
010 $a2020055181
020 $a9781108965682$q(paperback)
020 $a1108965687$q(paperback)
020 $z9781108963923$q(electronic book)
020 $z9781108967044$q(electronic book)
035 $a(OCoLC)1224161018
035 $a(OCoLC)on1224161018
035 $a 1039038276604786
040 $aDNLM/DLC$beng$erda$cDLC$dOCLCO$dOCLCA$dUKMGB$dOCLCO$dOCLCF$dOCLCA$dYDX$dOCLCO$dAAA$dOCLCO$dOCL
041 0#$aeng
042 $anbic
050 04$aRM333.5$b.M36 2021
060 #4$aWM200$bM2662 2021
082 00$a615.7882$223
245 00$aManagement of complex treatment-resistant psychotic disorders /$cedited by Dr. Michael A. Cummings, Dr. Stephen M. Stahl.
264 #1$aCambridge, United Kingdom ;$aNew York, NY :$bCambridge University Press,$c2021.
264 #4$c©2021.
300 $axxii, 522 pages :$bcolor illustrations ;$c23 cm.
336 $atext$btxt$2rdacontent.
337 $aunmediated$bn$2rdamedia.
338 $avolume$bnc$2rdacarrier.
504 $aIncludes bibliographical references and index.
505 0#$aPart I. Treatment Strategies -- Part II. Medication Reference Tables.
520 # $a"In community settings, the most common barriers to independent living, employment, and stable interpersonal relationships for patients suffering from schizophrenia-spectrum disorders or other psychotic disorders are negative symptoms and cognitive deficits. In contrast, severely mentally ill individuals, often incarcerated or chronically institutionalized, more frequently experience substantial barriers related to positive psychotic symptoms leading to problematic behaviors such as aggression or violence. This is not to say that among the chronically institutionalized severely mentally ill population that positive psychotic symptoms are the only, or even majority, source of problematic behaviors. A survey conducted within the California Department of State Hospitals, a circa 7000-bed system dedicated to the treatment of conserved and forensically committed patients, reviewed 839 episodes of aggression or violence by 88 persistently aggressive inpatients and found that 54% of such episodes were impulsive, 39% were predatory or instrumental, and 17% were psychotically driven. Nevertheless, amelioration or control of positive psychotic symptoms commonly forms the initial treatment focus among the severely mentally ill."--$cProvided by publisher.
650 22$aPsychopharmacology$xmethods.$376713
650 #0$aAntipsychotic drugs.$379203
650 #0$aPsychoses$xChemotherapy.$379204
650 #0$aDrug resistance.$379205
650 22$aPsychotic Disorders$xcomplications.$379207
650 22$aAntipsychotic Agents$xpharmacology.$379209
650 22$aDrug Resistance.$379210
650 #2$aAntipsychotic Agents.$379211
700 1#$aStahl, Stephen M.,$d1951-$350685
700 1#$aCummings, Michael A.$q(Michael Allen),$d1951-$eeditor.$379212